- Previous Close
4.4180 - Open
4.4000 - Bid --
- Ask --
- Day's Range
4.4000 - 4.5220 - 52 Week Range
3.8160 - 7.9300 - Volume
38,741 - Avg. Volume
47,261 - Market Cap (intraday)
212.373M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7400 - Earnings Date Nov 10, 2024 - Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.80
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
www.nanobiotix.comRecent News: NANO.PA
View MorePerformance Overview: NANO.PA
Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NANO.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NANO.PA
View MoreValuation Measures
Market Cap
212.37M
Enterprise Value
195.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.31
Price/Book (mrq)
--
Enterprise Value/Revenue
5.39
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-79.31%
Return on Assets (ttm)
-22.02%
Return on Equity (ttm)
--
Revenue (ttm)
42.2M
Net Income Avi to Common (ttm)
-33.47M
Diluted EPS (ttm)
-0.7400
Balance Sheet and Cash Flow
Total Cash (mrq)
66.33M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.55M